Page last updated: 2024-09-04

atrasentan and Prostatic Neoplasms

atrasentan has been researched along with Prostatic Neoplasms in 61 studies

Research

Studies (61)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (3.28)	18.2507
2000's	46 (75.41)	29.6817
2010's	13 (21.31)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ding, Y; Feng, NH; Jiang, WY; Qiao, D; Shao, N; Wang, JL; Wang, Y; Wu, Y; Zhang, SG; Zhang, XX	1
Agarwal, N; Carducci, MA; Garzotto, MG; Goldkorn, A; Higano, CS; Hussain, M; Lara, PN; Mack, PC; Moinpour, CM; Monk, JP; Quinn, DI; Tangen, CM; Thompson, IM; Twardowski, PW; Van Veldhuizen, PJ; Vogelzang, NJ	1
Taneja, SS	1
Agarwal, N; Carducci, MA; Cote, RJ; Datar, RH; Ely, B; Fink, LM; Garzotto, M; Goldkorn, A; Higano, CS; Hussain, M; Lara, P; Mack, PC; Monk, JP; Quinn, DI; Tangen, CM; Thompson, IM; Twardowski, P; Van Veldhuizen, PJ; Vogelzang, NJ; Xu, T	1
Fong, L; Friedlander, TW	1
Armstrong, AJ; Bacon, K; Creel, P; George, DJ; Hobbs, G; Hurwitz, H; McManus, TJ; Peer, CJ; Petros, WP; Younis, IR; Yu, JJ	1
Azim, HA; Mok, T	1
Becker, M; Börgermann, C; Hess, J; Rübben, H; Schenck, M; Vom Dorp, F	1
Dawson, NA	1
Carducci, M; Chin, JL; Love, W; Nelson, JB; Qian, J; Saad, F; Schulman, CC; Sleep, DJ; Steinberg, J	1
Armstrong, AJ; Creel, P; George, DJ; Gockerman, JP; Haley, S; Hurwitz, H; Jaffe, TA; Moore, C; Petros, W; Sleep, D; Turnbull, J; Yenser, S	1
Bazan, V; Bronte, G; Di Gaudio, F; Fanale, D; Gebbia, N; Rizzo, S; Russo, A	1
Danke, JR; Drake, JM; Henry, MD	1
Abdulkadir, SA; Roh, M	1
Beuzeboc, P; Neuzillet, Y; Villers, A	1
Espinosa, E; González, R; Merino, M; Pinto, A	1
Corn, PG; Dayyani, F; Gallick, GE; Logothetis, CJ	1
Castelo, B; Espinosa, E; Merino, M; Pinto, A; Redondo, A; Zamora, P	1
Norman, P	1
Carducci, MA; Walczak, JR	1
Bagnato, A; Battistini, B; Nelson, J; Nisen, P	1
Breul, J; Carducci, MA; Daliani, DD; Nabulsi, AA; Nelson, JB; Schulman, CC; Vogelzang, NJ; Zonnenberg, BA	1
Breul, J; Carducci, MA; Daliani, DD; Humerickhouse, RA; Nabulsi, AA; Nelson, JB; Padley, RJ; Schmitt, JL; Schulman, CC; Vogelzang, NJ; Weinberg, MA; Zonnenberg, BA	1
Beerlage, HP; De La Rosette, JJ; De Reijke, TM; Hendrikx, AJ; McKillop, CA	1
Nisen, P	1
Carr, RA; Groenewegen, G; Humerickhouse, RA; Isaacson, JD; Janus, TJ; Leahy, TW; Voest, E; Zonnenberg, BA	1
Carducci, MA; Lassiter, LK	1
Nelson, JB	3
Lee, D	1
Fisher, M	1
Brink, AK; Nelson, JB; Pecher, S; Pflug, BR	1
Fujimori, A; Fujiyasu, N; Koakutsu, A; Miyata, K; Sasamata, M; Sato, S; Shibasaki, K; Sudoh, K; Tanahashi, M; Tanaka, S; Yuyama, H	1
André, AK; Carr, RA; Humerickhouse, R; Kindler, HL; Ratain, MJ; Ryan, CW; Undevia, SD; Vogelzang, NJ; Vokes, EE; Wang, Q	1
Lee, D; Price, N; Reddy, K	1
Carducci, M; Jimeno, A	3
Nelson, JB; Smith, MR	1
Armstrong, AJ; Carducci, MA	1
Slovin, SF	1
Cella, D; Fishman, M; Mulani, P; Petrylak, DP; Teigland, C; Young, J	1
Choueiri, TK; Garcia, JA; Thakkar, SG	1
Chang, SS; Rumohr, JA	1
Kantoff, P; Kaufman, DS; Michaelson, MD; Oh, WK; Smith, MR	1
Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H	1
Akhavan, A; Bies, RR; Guruli, G; McHugh, KH; Nelson, JB; Pflug, BR; Strychor, SA; Zamboni, WC	1
Carducci, MA; Jimeno, A	1
Banerjee, S; Bonfil, D; Che, M; Cher, M; Hussain, M; Saliganan, A; Sarkar, FH; Wang, Z	1
Abrahamsson, PA; Carducci, MA; Dearnaley, DP; Isaacson, JD; Nelson, JB; North, SA; Saad, F; Schulman, CC; Sleep, DJ	1
Tan, W	1
Lalich, M; Liu, G; McNeel, DG; Wilding, G	1
Fleshner, NE; Shahani, R; Zlotta, AR	1
Bova, GS; Chan-Tack, K; Hedican, SP; Magnuson, SR; Nelson, JB; Opgenorth, TJ; Simons, JW	1
Kantoff, PW; Kennedy, A; Majeed, N; Padley, RJ; Pollak, M; Tolcher, AW	1
Andre, A; Bowling, MK; Carducci, MA; Carr, RA; Donehower, R; Eisenberger, MA; Hosmane, BS; Isaacson, JD; Janus, TJ; Leahy, TL; Nelson, JB; Padley, RJ; Rogers, T; Sinibaldi, V	1
van der Boon, J	1

Reviews

22 review(s) available for atrasentan and Prostatic Neoplasms

Article	Year
Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer. International journal of cancer, 2013, Oct-01, Volume: 133, Issue:7 Topics: Atrasentan; Disease-Free Survival; Endothelin Receptor Antagonists; Humans; Immunotherapy; Male; Orchiectomy; Proportional Hazards Models; Prostatic Neoplasms; Pyrrolidines; Tissue Extracts	2013
Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life. Anti-cancer drugs, 2008, Volume: 19, Issue:6 Topics: Atrasentan; Cisplatin; Diphosphonates; Docetaxel; Humans; Male; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Receptors, Calcitriol; Taxoids	2008
Anti-endothelin drugs in solid tumors. Expert opinion on emerging drugs, 2010, Volume: 15, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Drug Delivery Systems; Drugs, Investigational; Endothelin Receptor Antagonists; Endothelins; Humans; Male; Models, Biological; Neoplasms; Prostatic Neoplasms; Pyrrolidines; Receptors, Endothelin; Signal Transduction	2010
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:12 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A	2011
Novel therapies for metastatic castrate-resistant prostate cancer. Journal of the National Cancer Institute, 2011, Nov-16, Volume: 103, Issue:22 Topics: Androstenes; Androstenols; Angiogenesis Inhibitors; Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Atrasentan; Benzamides; Bevacizumab; Biomarkers, Tumor; Bone Remodeling; Cancer Vaccines; Clinical Trials as Topic; Clusterin; Dasatinib; Denosumab; Endothelin-1; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; RANK Ligand; Receptor Cross-Talk; Receptors, Androgen; Signal Transduction; Sunitinib; Taxoids; Thiazoles; Tissue Extracts; Treatment Failure; Tumor Microenvironment; Xenograft Model Antitumor Assays	2011
Targeting the endothelin axis in prostate carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012, Volume: 33, Issue:2 Topics: Atrasentan; Bone and Bones; Carcinoma; Cell Proliferation; Clinical Trials as Topic; Endothelins; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrrolidines	2012
Atrasentan Abbott. Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:8 Topics: Animals; Antineoplastic Agents; Atrasentan; Cardiovascular System; Contraindications; Endothelin Receptor Antagonists; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A; Receptors, Endothelin; Structure-Activity Relationship	2002
Pharmacological treatments for prostate cancer. Expert opinion on investigational drugs, 2002, Volume: 11, Issue:12 Topics: Antibodies, Monoclonal; Atrasentan; Dendritic Cells; Diphosphonates; Genetic Therapy; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imidazoles; Male; Microtubules; Prostatic Neoplasms; Pyrrolidines; Radiopharmaceuticals; Zoledronic Acid	2002
The endothelin axis: emerging role in cancer. Nature reviews. Cancer, 2003, Volume: 3, Issue:2 Topics: Amino Acid Sequence; Antineoplastic Agents; Atrasentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Humans; Male; Neoplasms; Prostatic Neoplasms; Protein Conformation; Pyrrolidines; Receptor, Endothelin A; Receptors, Endothelin	2003
Endothelin receptor antagonists in the treatment of prostate cancer. Seminars in oncology, 2003, Volume: 30, Issue:5 Topics: Androgen Antagonists; Apoptosis; Atrasentan; Bone Neoplasms; Bosentan; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Forecasting; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Sulfonamides; Treatment Outcome	2003
Endothelin inhibition: novel therapy for prostate cancer. The Journal of urology, 2003, Volume: 170, Issue:6 Pt 2 Topics: Antineoplastic Agents; Atrasentan; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines	2003
Atrasentan: targeting the endothelin axis in prostate cancer. Expert opinion on investigational drugs, 2004, Volume: 13, Issue:12 Topics: Atrasentan; Carcinoma; Clinical Trials, Phase III as Topic; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A	2004
Endothelin receptor antagonists. World journal of urology, 2005, Volume: 23, Issue:1 Topics: Apoptosis; Atrasentan; Biomarkers, Tumor; Clinical Trials as Topic; Disease Progression; Endothelin Receptor Antagonists; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Receptors, Endothelin; Treatment Outcome	2005
Future therapies in hormone-refractory prostate cancer. Urology, 2005, Volume: 65, Issue:5 Suppl Topics: Antibodies, Monoclonal; Atrasentan; Boronic Acids; Bortezomib; Diphosphonates; DNA, Antisense; Forecasting; Humans; Immunotherapy; Male; Prostatic Neoplasms; Pyrazines; Pyrrolidines; Receptors, Growth Factor; Thalidomide	2005
Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert review of anticancer therapy, 2005, Volume: 5, Issue:3 Topics: Apoptosis; Atrasentan; Bone Neoplasms; Clinical Trials as Topic; Disease Progression; Endothelins; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrrolidines	2005
Advanced prostate cancer: the future. The Canadian journal of urology, 2005, Volume: 12 Suppl 2 Topics: Antibodies, Monoclonal; Atrasentan; Forecasting; Humans; Immunotherapy, Active; Male; Prostatic Neoplasms; Pyrrolidines; Urology	2005
Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life? European urology, 2006, Volume: 49, Issue:5 Topics: Atrasentan; Drug Resistance, Neoplasm; Endothelin-1; Gonadal Steroid Hormones; Humans; Male; Neoplasm Metastasis; Prognosis; Prostatic Neoplasms; Pyrrolidines; Quality of Life	2006
Current chemotherapeutic approaches for androgen-independent prostate cancer. Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bevacizumab; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Endothelin-1; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Taxoids; Tubulin Modulators; Vascular Endothelial Growth Factor A	2006
Atrasentan: a rationally designed targeted therapy for cancer. Drugs of today (Barcelona, Spain : 1998), 2006, Volume: 42, Issue:5 Topics: Animals; Antineoplastic Agents; Atrasentan; Drug Delivery Systems; Drug Design; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic	2006
Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-15, Volume: 12, Issue:20 Pt 2 Topics: Antineoplastic Agents; Atrasentan; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Endothelin Receptor Antagonists; Female; Humans; Male; Prostatic Neoplasms; Pyrrolidines	2006
[Promising new treatment options for metastatic androgen-independent prostate cancer]. Actas urologicas espanolas, 2007, Volume: 31, Issue:6 Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides	2007
Endothelin receptor antagonists in cancer therapy. Cancer investigation, 2007, Volume: 25, Issue:8 Topics: Atrasentan; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Signal Transduction; Sulfonamides	2007

Trials

13 trial(s) available for atrasentan and Prostatic Neoplasms

Article	Year
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. The Lancet. Oncology, 2013, Volume: 14, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Survival Rate; Taxoids	2013
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-10, Volume: 32, Issue:11 Topics: Aged; Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Castration; Cell Count; Disease Progression; Docetaxel; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Grading; Neoplastic Cells, Circulating; Prognosis; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome	2014
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer, 2008, Nov-01, Volume: 113, Issue:9 Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Atrasentan; Disease Progression; Double-Blind Method; Endothelin-1; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Prognosis; Prostatic Neoplasms; Pyrrolidines; Treatment Outcome	2008
A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Oct-01, Volume: 14, Issue:19 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome	2008
Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. The Journal of urology, 2003, Volume: 169, Issue:3 Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Bone Remodeling; Bone Resorption; Collagen; Collagen Type I; Double-Blind Method; Endothelin-1; Humans; Male; Peptides; Prostatic Neoplasms; Pyrrolidines	2003
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Feb-15, Volume: 21, Issue:4 Topics: Acid Phosphatase; Adenocarcinoma; Aged; Antineoplastic Agents; Atrasentan; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Humans; L-Lactate Dehydrogenase; Male; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A; Treatment Outcome	2003
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-01, Volume: 9, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Atrasentan; Carcinoma; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrrolidines; Time Factors	2003
Clinical trials of atrasentan in hormone-refractory prostate cancer. Clinical prostate cancer, 2003, Volume: 2, Issue:2 Topics: Atrasentan; Disease Progression; Double-Blind Method; Endothelin-1; Humans; Male; Neoplasm Metastasis; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Survival Analysis; Treatment Outcome	2003
The endothelin-1 antagonist, atrasentan, improves time to progression and quality of life in hormone-refractory prostate cancer. Clinical prostate cancer, 2002, Volume: 1, Issue:2 Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Atrasentan; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Endothelin-1; Follow-Up Studies; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Risk Assessment; Treatment Outcome	2002
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jul-01, Volume: 10, Issue:13 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Atrasentan; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasms; Prostatic Neoplasms; Pyrrolidines; Receptors, Endothelin; Sex Factors; Time Factors	2004
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer, 2006, Aug-01, Volume: 107, Issue:3 Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Dyspnea; Edema; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Treatment Outcome; Zoledronic Acid	2006
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer, 2007, Nov-01, Volume: 110, Issue:9 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Atrasentan; Bone Neoplasms; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines	2007
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Apr-15, Volume: 20, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Atrasentan; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrrolidines; Salvage Therapy	2002

Other Studies

26 other study(ies) available for atrasentan and Prostatic Neoplasms

Article	Year
Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. The Journal of urology, 2014, Volume: 191, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids	2014
The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-10, Volume: 32, Issue:11 Topics: Antineoplastic Agents; Atrasentan; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Prostatic Neoplasms; Pyrrolidines; Taxoids	2014
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Atrasentan; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrrolidines; Taxoids	2014
[Value of targeted therapy for prostate cancer]. Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Atrasentan; Calcitriol; Drug Delivery Systems; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrrolidines; Sirolimus; Survival Rate; Thionucleotides	2008
Targeted therapy in prostate cancer--are we our own worst enemy? Cancer, 2008, Nov-01, Volume: 113, Issue:9 Topics: Atrasentan; Endothelin-1; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Pyrrolidines	2008
Bone-specific growth inhibition of prostate cancer metastasis by atrasentan. Cancer biology & therapy, 2010, Apr-15, Volume: 9, Issue:8 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Atrasentan; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Humans; Male; Mice; Prostatic Neoplasms; Pyrrolidines; Random Allocation; Xenograft Model Antitumor Assays	2010
Targeting the endothelin receptor in prostate cancer bone metastasis: Back to the mouse? Cancer biology & therapy, 2010, Apr-15, Volume: 9, Issue:8 Topics: Animals; Atrasentan; Bone Neoplasms; Disease Models, Animal; Endothelin Receptor Antagonists; Humans; Male; Mice; Molecular Targeted Therapy; Prostatic Neoplasms; Pyrrolidines	2010
[Inhibitors of the receptor A for endothelin-1]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2010, Volume: 20 Suppl 1 Topics: Atrasentan; Endothelin A Receptor Antagonists; Humans; Male; Prostatic Neoplasms; Pyrrolidines	2010
Atrasentan demonstrates survival benefit in hormone-refractory prostate cancer. Expert review of anticancer therapy, 2002, Volume: 2, Issue:3 Topics: Antineoplastic Agents; Atrasentan; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelin Receptor Antagonists; Hormones; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A; Survival Rate	2002
Prostate cancer: the right treatment for the right patient. Amsterdam, 17-18 January 2001. Prostate cancer and prostatic diseases, 2003, Volume: 6, Issue:2 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Brachytherapy; Combined Modality Therapy; Cryotherapy; Humans; Laparoscopy; Male; Neoplasm Staging; Patient Care Planning; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Pyrrolidines; Risk Factors	2003
New principles in the treatment of hormonal refractory prostate cancer. Scandinavian journal of urology and nephrology. Supplementum, 2003, Issue:212 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Atrasentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines	2003
Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines. The Prostate, 2004, Aug-01, Volume: 60, Issue:3 Topics: Atrasentan; Endothelin A Receptor Antagonists; Endothelin-1; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A; Tumor Cells, Cultured	2004
Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. European journal of pharmacology, 2004, May-25, Volume: 492, Issue:2-3 Topics: Analgesics, Non-Narcotic; Animals; Atrasentan; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin-1; Hindlimb; Male; Mice; Mice, SCID; Pain; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Sulfonamides; Time Factors; Viper Venoms	2004
Highlights from the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA. June 2004. Clinical prostate cancer, 2004, Volume: 3, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Medical Oncology; Middle Aged; Prognosis; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Risk Assessment; Societies, Medical; Survival Analysis; Treatment Outcome	2004
Fifth International Prostate Cancer Congress. 1-3 July 2005, Rio Grande, Puerto Rico. IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:9 Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Atrasentan; GPI-Linked Proteins; Histone Deacetylase Inhibitors; Humans; Male; Membrane Glycoproteins; Neoplasm Proteins; Prostatic Neoplasms; Pyrrolidines	2005
Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics. Current oncology reports, 2006, Volume: 8, Issue:2 Topics: Antineoplastic Agents; Atrasentan; Clinical Trials as Topic; Disease Progression; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Humans; Male; Neoplasms; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A; Receptors, Endothelin	2006
[Molecular-targeted therapy for hormone-refractory prostate cancer]. Hinyokika kiyo. Acta urologica Japonica, 2006, Volume: 52, Issue:6 Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D	2006
Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia (New York, N.Y.), 2006, Volume: 8, Issue:9 Topics: Animals; Apoptosis; Atrasentan; Bridged-Ring Compounds; Cell Survival; Endothelin A Receptor Antagonists; Humans; Ki-67 Antigen; Male; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Prostatic Neoplasms; Pyrrolidines; Taxoids	2006
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer research, 2007, Apr-15, Volume: 67, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; DNA, Neoplasm; Docetaxel; Drug Synergism; Endothelin A Receptor Antagonists; Humans; Male; Mice; Mice, SCID; NF-kappa B; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Taxoids; Xenograft Model Antitumor Assays	2007
Pharmacotherapy for prostate cancer: the role of hormonal treatment. Discovery medicine, 2007, Volume: 7, Issue:39 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Atrasentan; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Models, Biological; Prostatic Neoplasms; Pyrrolidines; Taxoids	2007
Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer research, 1996, Feb-15, Volume: 56, Issue:4 Topics: Apoptosis; Atrasentan; Base Sequence; Cell Division; Cell Line; Culture Media, Serum-Free; DNA Primers; DNA, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Epidermal Growth Factor; Fibroblast Growth Factor 2; Gene Expression; Growth Substances; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Male; Mitotic Index; Molecular Sequence Data; Neoplasm Metastasis; Platelet-Derived Growth Factor; Polymerase Chain Reaction; Prostate; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin B; Receptors, Endothelin; RNA, Messenger; Tumor Cells, Cultured	1996
ABT 627. A 147627, ABT 147627. Drugs in R&D, 1999, Volume: 2, Issue:1 Topics: Adenocarcinoma; Animals; Atrasentan; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Coronary Disease; Drugs, Investigational; Endothelin Receptor Antagonists; Humans; Male; Prostatic Neoplasms; Pyrrolidines	1999
Other novel agents: Rationale and current status as chemopreventive agents. Urology, 2001, Volume: 57, Issue:4 Suppl 1 Topics: Anticarcinogenic Agents; Atrasentan; Chromans; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Receptors, Endothelin; Somatomedins; Thiazoles; Thiazolidinediones; Troglitazone; Trypsin Inhibitor, Bowman-Birk Soybean; Trypsin Inhibitors	2001
Atrasentan prolongs time to progression in prostate cancer patients. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:7 Topics: Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Bone Neoplasms; Disease Progression; Drug Administration Schedule; Humans; Male; Multicenter Studies as Topic; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic	2001
Endothelin receptor antagonists in the treatment of prostate cancer. The Prostate, 2001, Oct-01, Volume: 49, Issue:2 Topics: Antineoplastic Agents; Atrasentan; Bone Neoplasms; Bone Resorption; Disease Progression; Endothelin Receptor Antagonists; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic	2001
New drug slows prostate-cancer progression. The Lancet. Oncology, 2002, Volume: 3, Issue:4 Topics: Antineoplastic Agents; Atrasentan; Clinical Trials as Topic; Disease Progression; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines	2002